地西他滨联合减量FLAG方案治疗老年高危急性髓系白血病的临床观察

Clinical effect of decitabine combined with reduced dose FLAG regimen on elderly patients with high-risk acute myeloid leukemia

目的 探讨地西他滨与减量FLAG方案治疗老年高危急性髓系白血病(AML)的效果。方法 选取2016年1月至2021年1月收治的老年高危AML患者60例。根据治疗方法不同分为对照组与观察组,每组30例。对照组用FLAG方案,观察组用地西他滨联合减量FLAG方案。比较两组疗效、不良反应、总生存时间、无复发时间,以及治疗前后生活质量。结果 观察组完全缓解率、总缓解率高于对照组,差异有统计学意义(χ^(2)=5.841,P<0.05)。两组不良反应(如口腔溃疡、药物性肝损害、消化道反应、感染与骨髓抑制等)比较,差异未见统计学意义(P>0.05)。观察组总生存时间与无复发时间长于对照组,差异有统计学意义(P<0.05)。结论 老年高危AML应用地西他滨联合减量FLAG方案治疗,不会明显增加不良反应,但可显著提高疗效,延长生存时间。

Objective To investigate the effect of decitabine and reduced FLAG regimen on elderly high-risk acute myeloid leukemia( AML). Methods Sixty elderly patients with high-risk AML treated from January 2016 to January 2021 were selected. According to different treatment methods,they were divided into control group and observation group,with 30 cases in each group. The control group was treated with FLAG scheme,and the observation group was treated with decitabine combined with reduction flag scheme. The efficacy,adverse reactions,overall survival time,recurrence free time and quality of life before and after treatment were compared between the two groups. Results The complete remission rate and total remission rate in the observation group were significantly higher than those in the control group( χ^(2)= 5.841,P<0.05). There was no significant difference between the two groups in adverse reactions( such as oral ulcer,drug-induced liver damage,gastrointestinal reaction,infection and bone marrow suppression) between the two groups( P>0.05). The total survival time and recurrence free time in the observation group were longer than those in the control group,and the difference was significant(P<0.05). Conclusions Decitabine combined with reduced FLAG regimen in the treatment of elderly high-risk AML will not significantly increase adverse reactions,but can significantly improve the curative effect and prolong the survival time.